Special Issues Concerning Postmenopausal Hormone Replacement Therapy and Breast Cancer

  • Peter M. Ravdin
Part of the Clinical Perspectives in Obstetrics and Gynecology book series (CPOG)


Over the past decade there have been several studies that have suggested that long-term use of hormone replacement therapy (HRT) with estrogens by postmenopausal women, may improve overall life expectancy.1–4 This is due largely to dramatic reductions in risk of cardiovascular risk. Other favorable effects have been noted such as a reduction in osteoporosis. Thus there continues to be a strong interest in taking HRT and a stronger rationale for taking them on a long-term basis, and not merely for a brief period for climacteric symptoms.5


Breast Cancer Breast Cancer Risk Endometrial Cancer Hormone Replacement Therapy Develop Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Am J Epidemiol 1988; 128: 606–614.PubMedGoogle Scholar
  2. 2.
    Petitti DB, Perlman JA, and Sidney S. Non-contraceptive estrogens and mortality: Longterm follow-up of women in the Walnut Creek Study. Obstet and Gyne. 1987; 70: 289–293.Google Scholar
  3. 3.
    Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991; 151: 75–78.PubMedCrossRefGoogle Scholar
  4. 4.
    Hunt K, Vessey M, McPherson K, and Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gyne. 1987; 94: 620–635.CrossRefGoogle Scholar
  5. 5.
    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B. Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 1038–1041.Google Scholar
  6. 6.
    Bush TL, Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In Korenman SG ed. the Menopause. Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Norwell, Mass; Sereno Symposia; 1990: 211–223.Google Scholar
  7. 7.
    Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prey Med. 1991; 20: 47–63.CrossRefGoogle Scholar
  8. 8.
    Jensen J, Nilas I, Christiansen C. Influence of menopause on serum lipids and lipoproteins. 1988; 10: 271–282.Google Scholar
  9. 9.
    Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. N Engl J Med 1985; 313: 1038–1043.PubMedCrossRefGoogle Scholar
  10. 10.
    Gambrell RD. Use of progestogens in postmenopausal women. Int J Fertil. 1989; 34: 315–321.PubMedGoogle Scholar
  11. 10.
    Gambrell RD. Use of progestogens in postmenopausal women. Int J Fertil. 1989; 34: 315–321.PubMedGoogle Scholar
  12. 12.
    Love RR, Newcombe PA, Wiebe DA. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer 1. 1990; 82: 1327–1332.CrossRefGoogle Scholar
  13. 13.
    Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339: 1–15, 71–85.Google Scholar
  14. 14.
    Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Ettinger B, Genant KH, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319–24.PubMedGoogle Scholar
  16. 16.
    Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least 2 years. Breast Cancer Res Treat. 1988; 12: 297–302.PubMedCrossRefGoogle Scholar
  17. 17.
    Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161: 1859–1864.PubMedGoogle Scholar
  18. 18.
    Shapiro S, Kelly JP, Rosenberg L, Kaaufman DW, Helmrich SP, Rosenshein NB, Lewis JL, Knapp RC, Stolley PD, Schottenfeld D. Risk of localized and wisespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313: 969–972.PubMedCrossRefGoogle Scholar
  19. 19.
    Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. Am J Obstet Gynecol 1979; 133: 537–547.PubMedGoogle Scholar
  20. 20.
    Ettinger B, Golditch IM, Friedman G. Gynecologic consequences of long-term unopposed estrogen replacement therapy. Maturitas Maturitas 1990; 12: 321–331.Google Scholar
  21. 21.
    Voigt LF, Weiss NS, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–277.PubMedCrossRefGoogle Scholar
  22. 22.
    Paganini-Hill A, Ross RK, Henderson BE.Endometrial cancer and patterns of use of oestrogen replacement therapy: A cohort study. Br J Cancer 1989; 59: 445–447.PubMedCrossRefGoogle Scholar
  23. 23.
    Persson I, Adami H-O, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. Br Med J. 1989, 298: 147–154.CrossRefGoogle Scholar
  24. 24.
    NSABP Protocol P-1. A clinical trial to determine the worth of tamoxifen for preventing breast cancer. NSABP Pittsburgh, PA.Google Scholar
  25. 25.
    Armstrong BK. Oestrogen therapy after menopause—boon or bane? Med J Aust. 1988; 148: 213–214.PubMedGoogle Scholar
  26. 26.
    Dupont WD, and Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Int Med. 1991; 151: 67–72.CrossRefGoogle Scholar
  27. 27.
    Dupont WD, Page DL, Rogers LW, and Parl FF. Influence of exogenous estrogens, proliferative disease, and other variables on breast cancer risk. Cancer 1989. 63: 948–957.PubMedCrossRefGoogle Scholar
  28. 28.
    Steinberg KK, Thacker SB, Smith J, Stroup DF, Zack; MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. 1991: 265: 1985–1990.Google Scholar
  29. 29.
    Gail MH, Brinton LA, Byar DP, Green SB, Schairer C, and Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81: 1879–1886.PubMedCrossRefGoogle Scholar
  30. 30.
    Carter CL, Allen C, and Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181–187.PubMedCrossRefGoogle Scholar
  31. 31.
    Creasman WT, Estrogen replacement therapy: is previously treated cancer a contraindication. Obstet Gynecol. 1991: 77: 308–312.PubMedCrossRefGoogle Scholar
  32. Theriault RL, Sellin RV. A clinical delemma: Estrogen replacement therapy in postmenopausal women with a background of primary breast cancer. Ann Oncol. 1991; 2: 709–717.Google Scholar
  33. 33.
    Nachtigall LE, Nachtigall RH, Nachtigall RD, and Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular disease and metabolic problems. Obstet Gynecol. 1979; 54: 74–79.PubMedCrossRefGoogle Scholar
  34. 34.
    Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293–297.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • Peter M. Ravdin

There are no affiliations available

Personalised recommendations